You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

13 search results for: real-world data

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and <b>Real-World</b> Effectiveness

expert video

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

21 min

Rhinology

Join Profs. Martin Wagenmann and Eugenio De Corso as they discuss type 2 inflammation in CRSwNP and explore real-world data on biologic efficacy.

Biologics in CRSwNP: Comparative Efficacy and <b>Real-World</b> Effectiveness

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

Emerging <b>Data</b> on Advanced Systemic Treatments for Children With AD

expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

15 min

Dermatology

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.

expert video

EAACI 2023 | What is New in the Treatment of Children

16 min

Dermatology

Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.

expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

5 min

Dermatology

Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

11 min

Dermatology

Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.

expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

18 min

Dermatology

The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

22 min

Dermatology

The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

69 min

Dermatology

Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.

expert video

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

43 min

Dermatology

This video presentation of the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga, Dr. Amy Paller, and Prof. Lisa Weibel. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating children with AD early in the disease course, and the emerging clinical and real-world data on the use of advanced systemic treatments for children with AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: TaiwanChange country/region